glp 1 period late The biggest GLP-1 news of 2026 dropped today and most people have no idea yet. Eli Lilly's retatrutide just cleared its biggest Phase 3 trial. The numbers are unlike anything we've seen GLP-1-based therapies for type 2

Association between obesity and selected morbidities: A study of BRICS countries

Aphaia Pharma Headquarters: Switzerland Technology: oral glucose formulation Lead candidate: APH-012 As disruptions in the guts natural responses to food intake are linked to metabolic diseases, such as obesity, Swiss biotech company Aphaia Pharma has come up with a way to restore these said natural responses, different from conventional obesity therapies like GLP-1 agonists

Originally developed to treat Type 2 diabetes, GLP-1 receptor agonists gained attention when clinicians noticed that patients taking them were also losing a meaningful amount of weight

2019 Nov;29(11):1151-1167

Kumar, C